Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Receivables (2020 - 2023)

Revolution Medicines has reported Receivables over the past 4 years, most recently at $1.3 million for Q4 2023.

  • Quarterly results put Receivables at $1.3 million for Q4 2023, down 73.16% from a year ago — trailing twelve months through Dec 2023 was $1.3 million (down 73.16% YoY), and the annual figure for FY2023 was $1.3 million, down 73.16%.
  • Receivables for Q4 2023 was $1.3 million at Revolution Medicines, up from $309000.0 in the prior quarter.
  • Over the last five years, Receivables for RVMD hit a ceiling of $12.8 million in Q4 2020 and a floor of $309000.0 in Q3 2023.
  • Median Receivables over the past 4 years was $5.4 million (2022), compared with a mean of $5.3 million.
  • Biggest five-year swings in Receivables: decreased 13.83% in 2022 and later tumbled 93.74% in 2023.
  • Revolution Medicines' Receivables stood at $12.8 million in 2020, then crashed by 53.63% to $5.9 million in 2021, then decreased by 21.18% to $4.7 million in 2022, then plummeted by 73.16% to $1.3 million in 2023.
  • The last three reported values for Receivables were $1.3 million (Q4 2023), $309000.0 (Q3 2023), and $2.5 million (Q2 2023) per Business Quant data.